About Pluristem Therapeutics (NASDAQ:PSTI)
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio-3.97
Forward P/E Ratio-5.52
Sales & Book Value
Annual Sales$2.85 million
Price / Sales49.41
Price / CashN/A
Book Value$0.31 per share
Price / Book4.10
EPS (Most Recent Fiscal Year)($0.32)
Return on Equity-77.44%
Return on Assets-61.88%
Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions
What is Pluristem Therapeutics' stock symbol?
Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."
How were Pluristem Therapeutics' earnings last quarter?
Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.08. View Pluristem Therapeutics' Earnings History.
What price target have analysts set for PSTI?
4 equities research analysts have issued 12-month price targets for Pluristem Therapeutics' shares. Their predictions range from $3.00 to $5.00. On average, they anticipate Pluristem Therapeutics' stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Pluristem Therapeutics.
What are Wall Street analysts saying about Pluristem Therapeutics stock?
Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
- 1. Maxim Group analysts commented, "Pluristem announced a joint project with Indiana University to evaluate PLX- R18 cells in Acute Radiation Syndrome (ARS). The study will be supported with $2.5M in grant funding, and data from the first year of the study will be used to further support a BLA filing." (4/23/2018)
- 2. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (3/27/2018)
Who are some of Pluristem Therapeutics' key competitors?
Some companies that are related to Pluristem Therapeutics include Mesoblast (MESO), CASI Pharmaceuticals (CASI), Scholar Rock (SRRK), Nightstar Therapeutics (NITE), Vericel (VCEL), Surface Oncology (SURF), PDL BioPharma (PDLI), Idera Pharmaceuticals (IDRA), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Osiris Therapeutics (OSIR), Cellular Biomedicine Group (CBMG), Allena Pharmaceuticals (ALNA), Agenus (AGEN) and Jounce Therapeutics (JNCE).
Who are Pluristem Therapeutics' key executives?
Pluristem Therapeutics' management team includes the folowing people:
- Mr. Zami Aberman, Chairman & Co-CEO (Age 64)
- Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 47)
- Mr. Erez Egozi, CFO, Treasurer & Sec. (Age 44)
- Mr. Boaz Leshem, VP Operations & Manufacturing (Age 58)
- Efrat Kaduri, Head of Investor & PR
Has Pluristem Therapeutics been receiving favorable news coverage?
Media coverage about PSTI stock has been trending somewhat positive on Sunday, according to Accern. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of 0.20 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Pluristem Therapeutics' major shareholders?
Which institutional investors are selling Pluristem Therapeutics stock?
How do I buy shares of Pluristem Therapeutics?
Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pluristem Therapeutics' stock price today?
One share of PSTI stock can currently be purchased for approximately $1.27.
How big of a company is Pluristem Therapeutics?
Pluristem Therapeutics has a market capitalization of $140.80 million and generates $2.85 million in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Pluristem Therapeutics employs 183 workers across the globe.
How can I contact Pluristem Therapeutics?
Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-8607 or via email at [email protected]
MarketBeat Community Rating for Pluristem Therapeutics (PSTI)MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.